NYSE:ABBVAbbVie Stock Price, Forecast & News

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ABBV stock has decreased by 13.5% and is now trading at $73.37. View which stocks have been mosted impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AbbVie.

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, May 1st 2020. View our earnings forecast for AbbVie.

AbbVie will be holding an earnings conference call on Friday, May 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AbbVie Inc (NYSE:ABBV) announced its quarterly earnings results on Friday, February, 7th. The company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.02. The company had revenue of $8.70 billion for the quarter, compared to analysts' expectations of $8.68 billion. AbbVie had a net margin of 23.69% and a negative return on equity of 162.54%. The firm's revenue for the quarter was up 4.8% on a year-over-year basis. During the same period last year, the company earned $1.90 EPS. View AbbVie's earnings history.

AbbVie declared a quarterly dividend on Thursday, February 20th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.18 per share on Friday, May 15th. This represents a $4.72 dividend on an annualized basis and a dividend yield of 6.43%. The ex-dividend date is Tuesday, April 14th. View AbbVie's dividend history.

AbbVie announced that its Board of Directors has initiated a share repurchase plan on Thursday, December 13th 2018, which allows the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 3.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's leadership believes its stock is undervalued.

AbbVie updated its FY20 earnings guidance on Friday, February, 7th. The company provided earnings per share guidance of $9.61-9.71 for the period, compared to the Thomson Reuters consensus estimate of $9.78.

14 analysts have issued 1 year price objectives for AbbVie's stock. Their forecasts range from $78.00 to $105.00. On average, they expect AbbVie's share price to reach $91.83 in the next year. This suggests a possible upside of 25.2% from the stock's current price. View analysts' price targets for AbbVie.

News coverage about ABBV stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AbbVie earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutAbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Pacira Biosciences (PCRX) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and AT&T (T).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by a number of retail and institutional investors. Top institutional investors include Park National Corp OH (0.01%), Thomasville National Bank (0.01%), Neville Rodie & Shaw Inc. (0.01%), Woodstock Corp (0.01%), Fulton Bank N.A. (0.01%) and First National Bank of Mount Dora Trust Investment Services (0.00%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase. View institutional ownership trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, Cullinan Associates Inc., Pensionfund DSM Netherlands, Blackhawk Capital Partners LLC., First National Bank of Mount Dora Trust Investment Services, Fulcrum Equity Management, Birch Capital Management LLC, and Thomasville National Bank. View insider buying and selling activity for AbbVie.

ABBV stock was acquired by a variety of institutional investors in the last quarter, including Neville Rodie & Shaw Inc., IMS Capital Management, Woodstock Corp, Fulton Bank N.A., Bath Savings Trust Co, Nelson Van Denburg & Campbell Wealth Management Group LLC, and Deane Retirement Strategies Inc.. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase. View insider buying and selling activity for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $73.37.

AbbVie has a market capitalization of $108.34 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe. View additional information about AbbVie.

The official website for AbbVie is http://www.abbvie.com/.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.